Ingavirin, 90 mg capsules 10 pcs

Antiviral drug.

In preclinical and clinical studies demonstrated the effectiveness of Ingavirin® against influenza viruses of type A (A(H1N1), including pandemic strain A(H1N1)pdm09 (“pig”), A(H3N2), A(H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, including coxsackievirus and rhinovirus. In clinical research in outpatients with mild course COVID-19 Ingavirin® shortened time to clinical recovery.

The mechanism of action is realized at the level of infected cells through activation of innate immunity factors suppressed by viral proteins. Experimental studies showed that Ingavirin® increases the expression of the interferon receptor of the first type IFNAR on the surface of epithelial and immunocompetent cells. The increase in the density of interferon receptors leads to increased sensitivity of cells to signals of endogenous interferon.

The process is accompanied by activation (phosphorylation) of protein-transmitter STAT1, transmitting signals to the cell nucleus for induction of synthesis of antiviral genes. It was shown that under infection conditions the preparation activates synthesis of antiviral effector protein MxA (early antiviral response factor inhibiting intracellular transport of ribonucleoprotein complexes of various viruses) and phosphorylated form of PKR inhibiting translation of viral proteins thus slowing down and stopping viral reproduction process.

The action of Ingavirin® preparation is based on significant decrease of cytopathic and cytodestructive virus action signs, reducing the number of infected cells, restriction of pathological process, normalization of cell composition and structure and tissue morphological pattern in the infectious process zone both at early and late stages.

Anti-inflammatory activity is caused by the suppression of production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-α), interleukins (IL-1β and IL-6), the decrease of myeloperoxidase activity.

In experimental studies it was shown that combined usage of Ingavirin® with antibiotics improves the efficiency of therapy on the model of bacterial sepsis including that caused by penicillin – resistant strains of Staphylococcus aureus.

The conducted experimental toxicological studies demonstrate the low level of toxicity and high safety profile of the drug.

According to the parameters of acute toxicity Ingavirin® belongs to the 4th class of toxicity – “Low-toxic substances” (by determining the LD50 in acute toxicity experiments lethal doses of the drug were not determined).

The drug has no mutagenic, immunotoxic, allergic and carcinogenic properties. Ingavirin® has no effect on reproductive function, has no embryotoxic and teratogenic effect.

There is no effect of Ingavirin® on the hematopoietic system when using the age appropriate dose in the recommended scheme and course.

absorption and distribution.

In the experiment using the radioactive label it was found: the drug quickly enters the blood from the gastrointestinal tract, distributing to internal organs. Maximum concentrations in blood, plasma and most organs are reached 30 minutes after drug administration. AUC values (area under the pharmacokinetic curve “concentration – time”) of kidney, liver and lung are slightly higher than AUC in blood (43.77 µg.h/g). The AUC values for the spleen, adrenal glands, lymph nodes and thymus are lower than the blood AUC. MRT (Mean Drug Retention Time) in blood is 37.2 hours.

When administered once daily the drug is accumulated in internal organs and tissues. In this case qualitative characteristics of pharmacokinetic curves after each drug administration are identical: rapid increase of the drug concentration after each administration in 0.5-1 hour after the administration and then slow decrease by 24 hours.

Metabolism.

The drug is not metabolized in the body and is excreted unchanged.

Elimation.

The main process of excretion occurs within 24 hours. During this period 80 % of taken dose is eliminated: 34.8 % is eliminated in the time interval from 0 to 5 hours and 45.2 % in the time interval from 5 to 24 hours. Of these, 77 % are excreted through the intestine and 23 % – through the kidneys.

Metabolism.

The drug is not metabolized in the body and is excreted unchanged.

Elimation.

The main process of excretion occurs within 24 hours. During this period 80 % of taken dose is eliminated: 34.8 % is eliminated in the time interval from 0 to 5 hours and 45.2 % in the time interval from 5 to 24 hours. Of these, 77% are excreted through the intestines and 23% through the kidneys.

Indications

Active ingredient

Composition

One capsule contains:

active ingredient: imidazolylethanamide pentandioic acid (vitaglutam) in terms of 100% substance – 90.00 mg;

excipients: lactose monohydrate, potato starch, colloidal silica (aerosil), magnesium stearate;

solid gelatin capsules:

for a dose of 90 mg -titanium dioxide E 171, crimson [Ponceau 4 R] dye E 124, azorubin dye E 122, quinoline yellow dye E 104, gelatin;

the composition of the logo ink: shellac, E 1520 propylene glycol, E 171 titanium dioxide.

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

There have been no reported cases of overdose of Ingavirin® to date.

Pregnancy use

Similarities